A Long-term Follow-up Study of Patients Who Received VOR33

Stopped early

Conditions studied: Leukemia, Myeloid, Acute

In brief

VOR33 long-term follow-up (LTFU) study

Key facts

Study ID

NCT05309733

Run by

Vor Biopharma

People needed

10

Starts

2022-04-15

Expected to finish

2025-05-28

Last updated by the study team

2025-07-29

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A patient is included in this study if he/she:
• Has received any part of or all of a VOR33 infusion

You may not qualify if…

• There are no exclusion criteria.

Where it is running

• University of California San Diego Moores Cancer Center — La Jolla, California, United States
• Miami Cancer Institute — Miami, Florida, United States
• National Institutes of Health, Clinical Center — Bethesda, Maryland, United States
• Washington University School of Medicine Siteman Cancer Center — St Louis, Missouri, United States
• John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• University Hospitals Seidman Cancer Center — Cleveland, Ohio, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States
• Hôpital Maisonneuve-Rosemont — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.